Extramedullary disease (EMD) is historically difficult to treat. Mezigdemide was deliberately developed with medicinal chemistry that allows it to penetrate solid tissues. This unique property enables it to effectively target EMD, a key differentiator from traditional IMiDs which are less effective in this setting.
While mezigdemide is a potent myelosuppressive agent that causes low neutrophil counts, the observed incidence of febrile neutropenia and serious, complex infections is reassuringly low. This suggests the neutropenia may be qualitatively different or that the drug's immune-enhancing effects offer a compensatory protective benefit.
Unlike lenalidomide, which modulates CK1-alpha and can select for p53-mutated cells leading to a risk of secondary leukemia/MDS, both iberdomide and mezigdemide do not share this off-target effect. This critical safety difference makes them promising candidates for long-term use, such as in maintenance therapy.
The lack of CELMoD approvals is not due to ineffectiveness but the evolving regulatory landscape where single-arm trials are insufficient. The high efficacy of bispecifics and CAR-Ts raised the approval bar, forcing CELMoD development into larger, active-controlled trials, delaying access to these convenient oral agents.
Unlike IMiDs (lenalidomide) which only close the Cereblon E3 ligase complex by 15-20%, mezigdemide achieves 100% closure. This leads to more robust degradation of key proteins, causing powerful direct myeloma cell destruction and enhanced immune activation, earning it the nickname 'CAR T in a pill.'
In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.